2021
Improved outcomes and staging in non-small-cell lung cancer guided by a molecular assay
Gupta AR, Woodard GA, Jablons DM, Mann MJ, Kratz JR. Improved outcomes and staging in non-small-cell lung cancer guided by a molecular assay. Future Oncology 2021, 17: 4785-4795. PMID: 34435876, PMCID: PMC9039775, DOI: 10.2217/fon-2021-0517.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorCarcinogenesisCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantClinical Decision-MakingDatasets as TopicDisease-Free SurvivalGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLung NeoplasmsMolecular Diagnostic TechniquesNeoplasm Recurrence, LocalNeoplasm StagingPneumonectomyProspective StudiesReal-Time Polymerase Chain ReactionRisk AssessmentConceptsCell lung cancerUndetectable metastasesLung cancerCell lung cancer patientsDisease-free survivalAdjuvant chemotherapy decisionsTime of surgeryLung cancer patientsSurgical resectionComplete resectionProspective studyCancer patientsChemotherapy decisionsResectionMolecular assaysPatientsPredictive benefitMetastasisCancerMortalityQuantitative PCRExpression profilesEarly stagesAssaysSurgeryMolecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non–Squamous Non–Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy
Woodard GA, Kratz JR, Haro G, Gubens MA, Blakely CM, Jones KD, Mann MJ, Jablons DM. Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non–Squamous Non–Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy. Clinical Lung Cancer 2021, 22: 587-595. PMID: 34544620, DOI: 10.1016/j.cllc.2021.08.008.Peer-Reviewed Original ResearchConceptsMolecular risk stratificationAdjuvant chemotherapyDisease-free survivalEGFR mutation statusAdjuvant interventionRisk stratificationEGFR patientsNSCLC patientsEGFR statusMutation statusSmall cell lung cancer patientsNon-squamous NSCLC patientsCell lung cancer patientsStage IA NSCLCStage IB patientsThird-generation TKIsEarly-stage NSCLCNon-Squamous NonLung cancer patientsEarly-stage cohortIB patientsProspective studyResidual diseaseCancer patientsEGFR mutations
2016
Hybrid minimally invasive Ivor Lewis esophagectomy after neoadjuvant chemoradiation yields excellent long‐term survival outcomes with minimal morbidity
Woodard GA, Crockard JC, Clary‐Macy C, Zoon‐Besselink C, Jones K, Korn WM, Ko AH, Gottschalk AR, Rogers SJ, Jablons DM. Hybrid minimally invasive Ivor Lewis esophagectomy after neoadjuvant chemoradiation yields excellent long‐term survival outcomes with minimal morbidity. Journal Of Surgical Oncology 2016, 114: 838-847. PMID: 27569043, DOI: 10.1002/jso.24409.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCarcinomaChemoradiotherapy, AdjuvantEsophageal NeoplasmsEsophagectomyFemaleFollow-Up StudiesHumansLaparoscopyMaleMiddle AgedMinimally Invasive Surgical ProceduresNeoadjuvant TherapyNeoplasm Recurrence, LocalNeuroendocrine TumorsPostoperative ComplicationsProspective StudiesSurvival AnalysisThoracotomyTreatment OutcomeConceptsNeoadjuvant chemoradiationEsophagectomy approachesLong-term overall survival rateInvasive Ivor Lewis esophagectomyLow perioperative morbidityPostoperative complication rateClear survival benefitFive-year survivalIvor Lewis esophagectomyMajority of patientsOverall survival rateEsophageal cancer patientsInvasive esophagectomy (MIE) approachPatients 58Hospital stayNeoadjuvant treatmentPerioperative complicationsPerioperative morbidityPostoperative complicationsProspective databaseClinical characteristicsOverall survivalSurvival benefitComplication rateMajor complications
2014
Prognostic Molecular Assay Might Improve Identification of Patients At Risk for Recurrence in Early-Stage Non–Small-Cell Lung Cancer
Woodard GA, Gubens MA, Jahan TM, Jones KD, Kukreja J, Theodore PR, Cardozo S, Jew G, Clary-Macy C, Jablons DM, Mann MJ. Prognostic Molecular Assay Might Improve Identification of Patients At Risk for Recurrence in Early-Stage Non–Small-Cell Lung Cancer. Clinical Lung Cancer 2014, 15: 426-432. PMID: 25258195, DOI: 10.1016/j.cllc.2014.07.004.Peer-Reviewed Original ResearchConceptsHigh-risk patientsLow-risk patientsStage IBNCCN criteriaNCCN guidelinesRisk stratificationHigh-risk clinicopathologic featuresEarly-stage NSCLC patientsAdjuvant chemotherapy recommendationsMonths of patientsMolecular risk stratificationCell lung cancerIdentification of patientsSmall cohort studiesMolecular risk assessmentBlinded chart reviewMolecular assaysAdjuvant chemotherapyChemotherapy recommendationsNonsquamous NSCLCStage IAChart reviewCohort studyNSCLC patientsRecurrence outcomes
2012
Normal Alcohol Metabolism after Gastric Banding and Sleeve Gastrectomy: A Case-Cross-Over Trial
Changchien EM, Woodard GA, Hernandez-Boussard T, Morton JM. Normal Alcohol Metabolism after Gastric Banding and Sleeve Gastrectomy: A Case-Cross-Over Trial. Journal Of The American College Of Surgeons 2012, 215: 475-479. PMID: 22770864, DOI: 10.1016/j.jamcollsurg.2012.06.008.Peer-Reviewed Original ResearchMeSH KeywordsCross-Over StudiesEthanolFemaleGastrectomyGastroplastyHumansMaleMiddle AgedObesity, MorbidProspective StudiesConceptsLaparoscopic adjustable gastric bandingLaparoscopic sleeve gastrectomyGastric bypass patientsGastric bandingAlcohol metabolismSleeve gastrectomyBypass patientsPostoperative gastric bypass patientsExcess weight lossAdjustable gastric bandingBariatric surgery patientsViable treatment optionPublic health concernGastric bypassBariatric proceduresBariatric surgeryPreoperative levelsSevere obesitySurgery patientsTreatment optionsPeak BACPatientsDrinking habitsTotal participantsGastrectomyEffect of Roux-en-Y gastric bypass on testosterone and prostate-specific antigen
Woodard G, Ahmed S, Podelski V, Hernandez-Boussard T, Presti J, Morton J. Effect of Roux-en-Y gastric bypass on testosterone and prostate-specific antigen. British Journal Of Surgery 2012, 99: 693-698. PMID: 22302466, DOI: 10.1002/bjs.8693.Peer-Reviewed Original ResearchConceptsProstate-specific antigenBody mass indexPSA levelsObese menGastric bypassSerum levelsWeight lossTestosterone levelsPSA massPercentage excess weight lossPlasma volumeExcess weight lossEffects of RouxSerum PSA levelsLow serum levelsSerum testosterone levelsConsecutive menMass indexSerum testosteroneProstate cancerMAIN OUTCOMETestosteroneDHEARYGBLongitudinal study
2010
One Year Improvements in Cardiovascular Risk Factors: a Comparative Trial of Laparoscopic Roux-en-Y Gastric Bypass vs. Adjustable Gastric Banding
Woodard GA, Peraza J, Bravo S, Toplosky L, Hernandez-Boussard T, Morton JM. One Year Improvements in Cardiovascular Risk Factors: a Comparative Trial of Laparoscopic Roux-en-Y Gastric Bypass vs. Adjustable Gastric Banding. Obesity Surgery 2010, 20: 578-582. PMID: 20186576, DOI: 10.1007/s11695-010-0088-0.Peer-Reviewed Original ResearchConceptsBiochemical cardiovascular risk factorsLaparoscopic adjustable gastric bandingAdjustable gastric bandingCardiovascular risk factorsTotal cholesterolRisk factorsGastric bandingGastric bypassHs-CRPLipoprotein cholesterolExcess weightHigh-sensitivity C-reactive proteinLow-density lipoprotein cholesterolSensitivity C-reactive proteinHigh-density lipoprotein cholesterolBackgroundCoronary artery diseaseConsecutive bariatric patientsPreventable risk factorsY Gastric BypassC-reactive proteinSingle academic institutionCause of deathSignificant weight lossPost-op valuesSignificant improvement
2009
Probiotics Improve Outcomes After Roux-en-Y Gastric Bypass Surgery: A Prospective Randomized Trial
Woodard GA, Encarnacion B, Downey JR, Peraza J, Chong K, Hernandez-Boussard T, Morton JM. Probiotics Improve Outcomes After Roux-en-Y Gastric Bypass Surgery: A Prospective Randomized Trial. Journal Of Gastrointestinal Surgery 2009, 13: 1198-1204. PMID: 19381735, DOI: 10.1007/s11605-009-0891-x.Peer-Reviewed Original ResearchMeSH KeywordsAdultBody Mass IndexConfidence IntervalsDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesGastric BypassHumansMaleMiddle AgedObesity, MorbidPatient SatisfactionPostoperative CarePostoperative ComplicationsProbabilityProbioticsProspective StudiesReference ValuesRisk AssessmentTreatment OutcomeWeight LossConceptsGastric bypass surgeryBacterial overgrowthProbiotic groupControl groupWeight lossBypass surgeryGreater percent excess weight lossPercent excess weight lossY Gastric Bypass SurgeryExcess weight lossProspective randomized trialsVitamin B12 levelsMethodsForty-four patientsQuality of lifeEnduring treatmentGastric bypassMorbid obesityB12 levelsPostoperative changesResultsAt 6Randomized trialsVitamin B12 availabilityProbiotic administrationGastrointestinal floraGI microbiota